

Turning a painkiller into a cancer killer

June 14 2010

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs (NSAIDs) like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in *Cancer Cell* on June 15, investigators at Sanford-Burnham Medical Research Institute (Sanford-Burnham) and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth. The study reveals that Sulindac shuts down cancer cell growth and initiates cell death by binding to nuclear receptor RXR α , a protein that receives a signal and carries it into the nucleus to turn genes on or off.

"Nuclear receptors are excellent targets for drug development," explained Xiao-kun Zhang, Ph.D., professor at Sanford-Burnham and senior author of the study. "Thirteen percent of existing drugs target nuclear receptors, even though the mechanism of action is not always clear."

RXR α normally suppresses tumors, but many types of [cancer cells](#) produce a truncated form of this [nuclear receptor](#) that does just the opposite. This study showed that shortened RXR α enhances [tumor growth](#) by stimulating other proteins that help cancer cells survive. Luckily, the researchers also found that Sulindac can be used to combat this deviant RXR α by switching off its pro-survival function and turning on apoptosis, a process that tells cells to self-destruct.

Sulindac is currently prescribed for the treatment of pain and fever, and to help relieve symptoms of arthritis. The current study demonstrates a new application for Sulindac as a potential anti-cancer treatment that

targets truncated RXR α protein in tumors. However, some NSAIDs have gotten a lot of bad press for their potentially dangerous cardiovascular side effects. To overcome this limitation, the researchers tweaked Sulindac, creating a new version of the drug - now called K-80003 - that both decreases negative consequences and increases binding to truncated RXR α .

"Depending on the conditions, the same protein, such as RXR α , can either kill cancer cells or promote their growth," Dr. Zhang said. "The addition of K-80003 shifts that balance by blocking survival pathways and sensitizing cancer cells to triggers of apoptosis."

More information: Zhou H, Liu W, Su Y, Wei Z, Liu J, Kolluri SK, Wu H, Cao Y, Chen J, Wu Y, Yan T, Cao X, Gao W, Molotkov A, Li W-G, Lin B, Zhang H-P, Yu J, Luo S-P, Zeng J-z, Duester G, Huang P-Q, Zhang X-k. NSAID Sulindac and Its Analog Bind RXR α and Inhibit RXR α -dependent AKT Signaling. Cancer Cell. Published online June 15, 2010.

Provided by Sanford-Burnham Medical Research Institute

Citation: Turning a painkiller into a cancer killer (2010, June 14) retrieved 28 April 2024 from <https://medicalxpress.com/news/2010-06-painkiller-cancer-killer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
